RGENRepligen Corporation

$173.84+42% 1Y

$173.84

$102.8752 weeks$194.62

RGEN in its own filings

RGEN's filing record carries 2 kinds of hard flag, each is shown beside the share of the whole market carrying the same one, because more than half of all companies carry at least one.

475

Events found in the filings · across 1,375 filings · the record starts in 1995

Hard flags: 2
Hard flags
Most recent filing: Oct 6, 2026
Most recent filing · Form 8-K
Record starts: Jun 29, 1995
Record starts · the earliest filing Ryufin holds for this name

Details›

Next results filingsame week as a year ago: expected around Oct 27, 2026
Restatement admitted (non-reliance)past_3y: 2024-09-18
Late periodic report5 occurrences: 2025-03-03
SEC comment-letter activity29 occurrences: 2025-09-10

SEC EDGAR submissions index and 8-K item codes; 4.02 and 1.03 items are confirmed against the filing text.

What the company said

The company's own words from its current reports to the SEC, newest first

Oct 6, 2026At the effective time of the First Merger (the “First Merger Effective Time”), each share of BioLife’s common stock, par value $0.001 per share (“BioLife Common Stock”), issued and outstanding immediately prior to the First Merger Effective Time (other than (i) any shares that were held by BioLife in treasury or owned …Acquisition or disposition completed · Form 8-K
Sep 15, 2026On September 10, 2026, Karen A. Dawes notified Repligen Corporation (“Repligen”) that she will be retiring from the Repligen Board of Directors (the “Board”) after over twenty years of distinguished service to Repligen, effective as of September 30, 2026.Director or officer change · Form 8-K
Sep 8, 2026As previously disclosed, on July 21, 2026, Repligen Corporation, a Delaware corporation (“Repligen”), entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Bravo Merger Sub I, Inc., a Delaware corporation and wholly owned subsidiary of Repligen (“Merger Sub 1”), Bravo Merger Sub II, LLC, a …Other event · Form 8-K
Jul 28, 2026Waltham, Massachusetts 02453.Earnings release · press release
Jul 22, 2026Merger Agreement On July 21, 2026, Repligen Corporation, a Delaware corporation (“Repligen”), entered into an Agreement and Plan of Merger (the “Merger Agreement”) by and among Repligen, Bravo Merger Sub I, Inc., a Delaware corporation and wholly owned subsidiary of Repligen (“Merger Sub 1”), Bravo Merger Sub II, LLC …Material agreement entered · Form 8-K
May 5, 2026Waltham, Massachusetts 02453.Earnings release · press release
Feb 24, 2026Waltham, Massachusetts 02453.Earnings release · press release
Jan 6, 2026On January 6, 2026, Repligen Corporation (the “Company”) announced that the Board of Directors (the “Board”) has elected Dr. Martin D. Madaus as Chair of the Board, effective March 13, 2026 (the “Effective Date”)Director or officer change · Form 8-K
Oct 28, 2025Waltham, Massachusetts 02453.Earnings release · press release